Stock Events

Stock Events

Theravance Biopharma 

$17.04
20
+$0.01+0.06%Thursday 13:30

Statistics

Day High
17.07
Day Low
17.02
52W High
21.03
52W Low
13.08
Volume
10,016,289
Avg. Volume
863,989
Mkt Cap
884.7M
P/E Ratio
7.59
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 10Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.31
0.15
0.62
1.08
Expected EPS
0.296667
Actual EPS
N/A

Financials

98.54%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
107.46MRevenue
105.9MNet Income

Analyst Ratings

$17.00Average Price Target
The highest estimate is ⁦17.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other serious diseases, competing in the respiratory and systemic treatment areas similar to Theravance's interests.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas overlapping with Theravance, including respiratory diseases.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie operates in the same biopharmaceutical field, focusing on immunology and chronic diseases, areas where Theravance also has interests.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, particularly in the development of medicines for serious medical conditions, similar to Theravance's mission.
AMGEN
AMGN
Mkt Cap251.94B
Amgen focuses on human therapeutics, with a broad range of treatments that could compete with Theravance's products in various therapeutic areas.
Biogen
BIIB
Mkt Cap37.49B
Biogen develops therapies for neurological and neurodegenerative diseases, potentially competing with Theravance's developments in related healthcare sectors.
Incyte
INCY
Mkt Cap24.54B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including for serious medical conditions that overlap with Theravance's focus areas.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is a global, science-led biopharmaceutical business that competes across several of the same therapeutic areas as Theravance, including respiratory diseases.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is a global healthcare company that offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing in areas relevant to Theravance's work.

About

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Show More
CEO
Rick E. Winningham
Employees
90
Country
United States
ISIN
KYG8807B1068
WKN
000A1137V

Listings

STU
DE
0TB.STU
BOATS
BOATS
TBPH.BOATS

0 Comments

Share your thoughts

FAQs

What is Theravance Biopharma stock price today?▼
The current price of TBPH is $17.04 USD — it has increased by +0.06% in the past 24 hours. Watch Theravance Biopharma stock price performance more closely on the chart.
What is Theravance Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Theravance Biopharma stocks are traded under the ticker TBPH.
Is Theravance Biopharma stock price growing?▼
TBPH stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Theravance Biopharma has showed a +15.53% increase.
What is Theravance Biopharma market cap?▼
Today Theravance Biopharma has the market capitalization of 884.7M
When is the next Theravance Biopharma earnings date?▼
Theravance Biopharma is going to release the next earnings report on November 10, 2026.
What were Theravance Biopharma earnings last quarter?▼
TBPH earnings for the last quarter are -0.11 USD per share, whereas the estimation was 0.07 USD resulting in a -251.72% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Theravance Biopharma revenue for the last year?▼
Theravance Biopharma revenue for the last year amounts to 107.46M USD.
What is Theravance Biopharma net income for the last year?▼
TBPH net income for the last year is 105.9M USD.
How many employees does Theravance Biopharma have?▼
As of November 7, 2026, the company has 90 employees.
In which sector is Theravance Biopharma located?▼
Theravance Biopharma operates in the Health & Wellness sector.
When did Theravance Biopharma complete a stock split?▼
Theravance Biopharma has not had any recent stock splits.
Where is Theravance Biopharma headquartered?▼
Theravance Biopharma is headquartered in GEORGE TOWN, GRAND CAYMAN, United States.